

CLINICAL STUDY REPORT - IN-TEXT TABLES, TABLES FIGURES AND GRAPHS, PATIENT AND INDIVIDUAL PATIENT DATA LISTINGS: ICH E3 TECHNICAL REQUISITES AND POSSIBLE SOLUTION IN SAS

Data handling and reporting in clinical trials with SAS
Seminario BIAS – Milano 22 / 02 / 2013

Angelo Tinazzi
Cytel Inc.
Geneva – Switzerland
angelo.tinazzi@cytel.com

Agenda

- **Introduction to ICH E3**
- **Key points in ICH E3 referring to statistical outputs production**
- **ICH E3 Additional Considerations**
- **Technical Solutions**
 - **Software requirements overview**
 - **In-house solutions**
 - **Facilitate the work of the medical writer**
 - **Other possible topics for discussion**
- **References**

Agenda

- **Introduction to ICH E3**
- Key points in ICH E3 referring to statistical outputs production
- ICH E3 Additional Considerations
- Technical Solutions
 - Software requirements overview
 - In-house solutions
 - Facilitate the work of the medical writer
 - Other possible topics for discussion
- References

Introduction to ICH E3

Structure and Content of Clinical Study Reports (CSR)

- CSRs describe the background, rationale, methodology and full results for a clinical study
- Called **integrated reports** as they cover clinical and statistical aspects
- Guideline ICH E3 on structure and content of CSRs: 53 pages of **guidance**
- Other Guidances
 - ICH E9 Statistical Principles for Clinical Trials
 - ICH M2 EWG The Electronic Common Technical Document(eCTD)
 - FDA Portable Document Format (PDF) Specifications

Introduction to ICH E3



E3 Implementation Working Group Q&A 7 June 2012

- It is a guidance not a set of rigid requirements or a **template**
- **Modifications** and **adaptions** that lead better display and communication of information are encouraged
- Some data in appendices are specific requirements of individual HA and should be submitted as appropriate
- **New sections** could be added if appropriate
- **Repetitions are allowed.** E.g. deaths listing vs AE with fatal outcome

Agenda

- Introduction to ICH E3
- **Key points in ICH E3 referring to statistical outputs production**
- ICH E3 Additional Considerations
- Technical Solutions
 - Software requirements overview
 - In-house solutions
 - Facilitate the work of the medical writer
 - Other possible topics for discussion
- References

Key points in ICH E3 referring to statistical outputs production

Obviously the TLFs programmed by biostat department are the source of information of CSR

- **In-text tables:** statistical outputs inserted in the body of the CSR, i.e sections 1 to 13 as per ICH E3.
- **End-text** - Section 14: Tables, Figures and Graphs Referred to but not Included in the text. When the statistical output will be presented outside the body of the report
- **Narratives:** detailing deaths, other SAE and significant AE in section 12.3.2
- **Subject/Patients Data Listings**
 - 16.1 Study Information
 - 16.1.6 Listing of patients receiving test drug(s)/investigational product(s) from specific batches, where more than one batch was used
 - 16.1.7 Randomisation scheme and codes (patient identification and treatment assigned)
 - 16.2 Patient Data Listings
 - 16.4 Individual Patient Data Listings

Key points in ICH E3 referring to statistical outputs production

The guidance gave also some instructions on the required contents of tables and listings. For example:

- 12.2.4. Listings of Adverse Events *All adverse events for each patient,, should be listed in appendix 16.2.7...the listing should be by investigator and by treatment....and should include: patient identifier, age, race....the adverse event (preferred term, reported term) ...*
- 12.4.2.2. Laboratory Individual Patient Changes *An analysis of individual patient changes by treatment should be given e.g. shift tables*
- Some template for figures, tables and listings are also provided. For example:
 - Disposition of patients (figure)
 - Listings of patients who discontinued therapy
 - Listings of patients and observations excluded from efficacy analysis
 - Number of patients excluded from the efficacy analysis

The guidance contains also instructions on «expected» statistical analysis to be taken in consideration for the SAP development (see also section 16.1.9)

Key points in ICH E3 referring to statistical outputs production

In-text tables

Table 1–1 Subject Disposition (Referring to Appendix 15.1 Table 15.1.1.1)

Subject Disposition - ITT Population				
Output ID: T_DISPO1 06JAN2012 14:24				
Characteristic	W (N=62) N (%)	K (N=60) N (%)	I (N=62) N (%)	Total (N=206) N (%)
All Screened Subjects				206
Safety Population	61 (98.4)	59 (98.3)	62 (100.0)	182 (88.3)
ITT Population	62 (100.0)	60 (100.0)	62 (100.0)	184 (89.3)
Per Protocol Population	45 (72.6)	36 (60.0)	43 (69.4)	124 (60.2)
Total number (%) of discontinued subjects	60 (96.8)	58 (96.7)	58 (93.5)	177 (85.9)
Reason For Discontinuation As Randomized	60 (100.0)	58 (100.0)	58 (100.0)	177 (100.0)
Adverse Event	9 (10.0)	10 (19.0)	14 (19.0)	23 (15.8)
Death	5 (8.3)	7 (12.1)	5 (8.6)	17 (9.6)
Inclusion And/Or Exclusion Criteria Not Full-filled	0 (0.0)	1 (1.7)	1 (1.7)	2 (1.1)
Subject Withdrew Consent	4 (6.7)	3 (5.2)	2 (3.4)	9 (5.1)
Progressive Disease	33 (55.0)	29 (50.0)	33 (56.9)	95 (53.7)
Symptomatic Deterioration	3 (5.0)	2 (3.4)	1 (1.7)	6 (3.4)
Others	9 (15.0)	5 (8.6)	5 (8.6)	20 (11.3)

Sponsor SDOT Tool

- RTF output: a **word table** that can be easily inserted into the CSR
- Include **CAPTION** for automatic reference once they are inserted in the CSR
- **Source** should be also mentioned (e.g. post-text table/listing)

Key points in ICH E3 referring to statistical outputs production

Post-text tables

15.2.1 : Progression Free Survival Time
Table 15.2.1.2 : All Subgroups - ITT Population

Characteristic	Statistics	W (N=35)		t (N=62)	
		n	Median (mo) [95% CI] HR [95% CI]	n	Median (mo) [95% CI] HR [95% CI]
Primary Tumor Site	Oropharynx	11	5.5 [3.1; 6.7] 1.47 [0.62; 3.45]	22	4.5 [4.0; 11.0]
	Hypopharynx	10	6.6 [5.6; 9.5] 1.37 [0.51; 3.73]		
	Oral cavity	15	5.7 [1.4; 6.9] 2.13 [0.77; 5.88]		
Tumor Grade	Well or Moderately differentiated	46	6.9 [4.3; 5.5] 1.01 [0.57; 1.78]		
	Poorly differentiated	25	5.6 [4.3; 12.5] 0.75 [0.37; 1.53]		

Median: Product-limit (Kaplan-Meier) estimates
Note: Hazard ratio of K or L 2 over t alone.
Note: Randomization strata used for stratification: Karnofsky performance status (from IVRS)

n	Median (mo) [95% CI] HR [95% CI]
11	5.5 [3.1; 6.7] 1.47 [0.62; 3.45]

Sponsor SDOT Tool

Complex output summarizing information coming from different PROCs e.g. LIFETEST (Median 95%CI) and PHREG (HR 95%CI) to save space and improve readability

Key points in ICH E3 referring to statistical outputs production

Post-text listings

```

15.3.20 : Special Adverse Events
Listing 15.3.20.5 : Listing of Subjects with Haemorrhages - S
-----
Actual
Treatment Subject
-----
c      03012003 AE Preferred term : EPISTAXIS NCI-CTC-Grade : GRADE 1 OR Relationship to :RELATED
          Symptoms as reported : EPISTAXIS MILD Relationship to :RELATED
          Start : 02AUG2010 Outcome : Relationship to :RELATED
          End : 18JAN2011 Serious AE : N Relationship to :RELATED
          not resolved Relationship to :RELATED
          not resolved Relationship to :RELATED
          Start : 10APR2010 N Relationship to :NOT RELATED
          End : 16APR2010
          AE Preferred term : LIP NCI-CTC-Grade : GRADE 1 OR Relationship to :RELATED
          HAEMORRHAGE MILD Relationship to :RELATED
          Symptoms as reported : BLEEDING Outcome : Relationship to :NOT RELATED
          ON LEVEL OF LIPS Recovered/resolved Relationship to :NOT RELATED
          Start : 10APR2010 Serious AE : N Relationship to :NOT RELATED
          End : 16APR2010
          AE Preferred term : SPONTANEOUS HAEMATOMA NCI-CTC-Grade : GRADE 1 OR Relationship to :RELATED
          Symptoms as reported : SPONTANEOUS HEMATOMAS MILD Relationship to :RELATED
          SPONTANEOUS HEMATOMAS ON HANDS Outcome : Relationship to :NOT RELATED
          Start : 02OCT2010 Recovered/resolved Relationship to :NOT RELATED
          End : 26OCT2010 Serious AE : N Relationship to :NOT RELATED
          AE Preferred term : HAEMATOMA NCI-CTC-Grade : GRADE 1 OR Relationship to :NOT RELATED
          Symptoms as reported : HEMATOMAS MILD Relationship to :NOT RELATED
          Start : 16JUN2011 Outcome : Relationship to :NOT RELATED
          End : 06JUL2011 Recovered/resolved Relationship to :NOT RELATED
          Serious AE : N Relationship to :NOT RELATED
-----
Dictionary Coding: MedDRA version 14.0.
    
```


Alternative solution can be implemented to avoid split in several pages when there are many information to report. e.g. adverse events listing

SAS Proc Report


Proc REPORT Tutorial. C. Zender. WUSS 2010
 Beyond the Basic: Advanced REPORT Procedure Tips and Tricks Updated for SAS 9.2. A. McMahon Booth. SAS Global Forum 2011

Key points in ICH E3 referring to statistical outputs production

Figures



EMF, EPS, WMF and CGM are recommended file formats



Sponsor Standard Graph Library

Should allow **B&W printing** without losing any information. Their display should be verified

Sponsor Standard Graph Library

Key points in ICH E3 referring to statistical outputs production

Subject Profile

Study 27298	Date of Birth: 12JUN1963	272980020001																																													
INDIVIDUAL FIGURES	Gender: Female																																														
Patients Profiles ↓ ↑	Race: Other, HISPANIC	<i>Click to view the Annotated CRF</i>																																													
	Initials: A-C	<i>Click to view the listings</i>																																													
	Status -End of Treatment: Withdrew Prematurely																																														
	Status -End of Study: Not Completed																																														
GLOBAL FIGURES Abnormal Values	Drug Exposure																																														
Vital Signs ↓ ↑	<i>Dummy Administrations are displayed using Number of Days since First Dose</i>																																														
Biochemistry ↓ ↑	List of distinct dummy doses administered to the overall population:																																														
Haematology ↓ ↑	0.25 (mL) 0.50 (mL) 0.75 (mL) 1.50 (mL) 7.50 (mL)																																														
Urinalysis ↓ ↑																																															
GLOBAL FIGURES Detail	Vital Signs (1 unscheduled visit(s) not displayed, refer to the detailed PDF Patient Profile)																																														
Vital Signs ↓ ↑	<i>Values are displayed using their corresponding Visit Code</i>																																														
Biochemistry ↓ ↑	<table border="1" style="width: 100%; text-align: center;"> <tr> <td>Systolic BP (mm Hg)</td> <td>132</td><td>138</td><td>132</td><td>146</td><td>102</td><td>106</td><td>114</td><td>120</td> </tr> <tr> <td>Diastolic BP (mm Hg)</td> <td>78</td><td>82</td><td>80</td><td>100</td><td>68</td><td>82</td><td>82</td><td>72</td> </tr> <tr> <td>Heart Rate (bpm)</td> <td>60</td><td>62</td><td>80</td><td>68</td><td>66</td><td>72</td><td>72</td><td>74</td> </tr> <tr> <td>Temperature (Celci [...])</td> <td>36.8 (C)</td><td>36.6 (C)</td><td>37.1 (C)</td><td>37.1 (C)</td><td>36.6 (C)</td><td>36.8 (C)</td><td>37.0 (C)</td><td>36.4 (C)</td> </tr> <tr> <td>Weight (Kg)</td> <td>102.5 (kg)</td><td>102.5 (kg)</td><td>105.7 (kg)</td><td>107.0 (kg)</td><td>104.3 (kg)</td><td></td><td></td><td>103.4 (kg)</td> </tr> </table>		Systolic BP (mm Hg)	132	138	132	146	102	106	114	120	Diastolic BP (mm Hg)	78	82	80	100	68	82	82	72	Heart Rate (bpm)	60	62	80	68	66	72	72	74	Temperature (Celci [...])	36.8 (C)	36.6 (C)	37.1 (C)	37.1 (C)	36.6 (C)	36.8 (C)	37.0 (C)	36.4 (C)	Weight (Kg)	102.5 (kg)	102.5 (kg)	105.7 (kg)	107.0 (kg)	104.3 (kg)			103.4 (kg)
Systolic BP (mm Hg)	132	138	132	146	102	106	114	120																																							
Diastolic BP (mm Hg)	78	82	80	100	68	82	82	72																																							
Heart Rate (bpm)	60	62	80	68	66	72	72	74																																							
Temperature (Celci [...])	36.8 (C)	36.6 (C)	37.1 (C)	37.1 (C)	36.6 (C)	36.8 (C)	37.0 (C)	36.4 (C)																																							
Weight (Kg)	102.5 (kg)	102.5 (kg)	105.7 (kg)	107.0 (kg)	104.3 (kg)			103.4 (kg)																																							
Haematology ↓ ↑	Laboratory Parameters (no unscheduled visit)																																														
Urinalysis ↓ ↑	<i>Values are displayed using Number of Days between Collection Date and First Dose</i>																																														
	<i>Values in blue indicate results less than lower normal limit. Values in red indicate results higher than upper normal limit.</i>																																														
	<table border="1" style="width: 100%; text-align: center;"> <tr> <td>Haemoglobin</td> <td>117</td><td>118</td><td>132</td><td>113</td><td>118</td><td>119</td><td>108</td><td>122</td> </tr> <tr> <td>White Blood Cell c [...]</td> <td>9.2</td><td>10.9</td><td>14.7</td><td>12.5</td><td>8.1</td><td>9.1</td><td>10.1</td><td>11.78</td> </tr> </table>		Haemoglobin	117	118	132	113	118	119	108	122	White Blood Cell c [...]	9.2	10.9	14.7	12.5	8.1	9.1	10.1	11.78																											
Haemoglobin	117	118	132	113	118	119	108	122																																							
White Blood Cell c [...]	9.2	10.9	14.7	12.5	8.1	9.1	10.1	11.78																																							

Sponsor Patient Profile Tool

Extremely useful for medical review but could be also provided for the section 16.4

Key points in ICH E3 referring to statistical outputs production

Narrative

Subject: 101004

Randomized Arm: NIC .15

Investigator: 101A

Drug and Dose at Event Onset: 30 mg/h of NIC .15

Serious Adverse Event (coded term [reported term]): COMA [COMA]

Subject 101004 was a 48-year-old white female. Her medical history included focal deficit (1988), headache (1988), loss of consciousness (1988), vomiting (1988), other medical condition (1977) and allergies (start date unknown). She began dosing with 30 mg/h of nic .15 on 28JAN1988 (Day 1). The subject discontinued the trial on 31JAN1988 (Day 4) due to death.

On 28JAN1988 (Day 1) the subject experienced a coma (severe) which was considered a serious adverse event (SAE). Though the event was considered serious, no reasons were provided on the case report form. At the time of the event, the subject was taking 30 mg/h of nic .15 and had been at this dose for 1 day. The SAE occurred on the first day of dosing with any study medication. Trial medication had an action of drug withdrawn as a result of the event. It is not known from the case report form if therapeutic measures were administered to treat the event.

Adverse events that occurred within a ± 3 -day window of the onset of the SAE included brain oedema (mild), hydrocephalus (severe), hyperglycaemia (mild), hypotension (severe), intracranial pressure increased (severe), subarachnoid haemorrhage (severe) and vasoconstriction (severe). Concomitant medications taken at the onset of the SAE included docusate sodium (stool softener), phenobarbital (sedative), potassium supplements (fluids) and ranitidine (decrease acidity).

The subject had the following abnormal lab tests at baseline: high creatine kinase [411 U/L, range = (15 - 195)], high chloride [112 mmol/L, range = (97 - 107)], high leukocytes [21 U/L, range = (3 - 20)], low partial pressure carbon dioxide [2394 Pa, range = (4655 - 5985)] and high partial pressure oxygen [31654 Pa, range = (9975 - 13965)]. The subject had no on-study lab tests with results different than baseline on or prior to the start day of the event. On the closest lab test day subsequent to the start of the event, the subject had the following on-study lab tests with results different than baseline: low blood urea nitrogen [2.142 mmol/L, range = (2.499 - 7.497), BL = normal], low carbon dioxide [91.308 mg/dL, range = (100.004 - 130.44), BL = normal], low creatinine [0.053040001768 mmol/L, range = (0.05746 - 0.10608), BL = normal] and normal leukocytes [11 U/L, range = (3 - 20), BL = high].

The investigator considered the AE to be related to study medication. The final outcome of the event was reported as recovered/resolved on 31JAN1988 (Day 4).

Generated with JMP® Clinical

Developing a Complete Picture of Patient Safety in Clinical Trials. RC Zink. RD Wolfinger. SESUG 2012

Usually written by the MW, but **automation** can be implemented especially for big trials

Key points in ICH E3 referring to statistical outputs production

As per FDA Portable Document Format (PDF) Specifications – Style Requirements

■ US Letter

- **Margins** as recommended by FDA PDF Specification. In general settings of 1 inch on each side of the page should be also enough to allow printing on A4 as well
- Font sizes ranging from 9 to 12 points
 - Times New Roman 12-point font is recommended for narrative text
 - For tables generally, **point sizes 9-10** are recommended for tables; smaller point sizes should be avoided. Ten point fonts are recommended for footnotes.

Key points in ICH E3 referring to statistical outputs production

SAS options/statements for controlling paper size and styles

Paper Size, Orientation and Margins with SAS options

```
option papersize="LETTER" orientation=LANDSCAPE
    topmargin="1in" bottommargin="1in" leftmargin="1in" rightmargin="1in";
```

Setting fonts and size by modifying a template

```
proc template;
  define style MyStyle / store=library.styles;
    parent = styles.sasdocPrinter;
    replace fonts /
      'TitleFont2' = ("Courier New", 9pt)
      'TitleFont'  = ("Courier New", 9pt)
      'TextFont'   = ("Courier New", 9pt);
```

Zoom, Zoom: Get your document to scale on all paper size. D. O'Connor. SAS Global Forum 2010

Key points in ICH E3 referring to statistical outputs production

SAS options/statements for controlling paper size and styles

ODS Options e.g. the 'page x of y' dilemma

```
ods escapechar="^";  
title1 j=1 "Study Drug: MyDrug"  
      j=r ' Page ^{thispage} of ^{lastpage}';  
ods pdf file="MyFile.pdf" style=MyStyle;  
      /*Other SAS Statements*/  
ods pdf close;
```

It controls special sequence for **in-line formatting**
(e.g. PDF, RTF, HTML)

The Greatest Hits: ODS Essentials Every User Should Know. C. Zender. NESUG 2011
Advanced RTF Layout with SAS. K. Glab. PhUSE 2007

Key points in ICH E3 referring to statistical outputs production

SAS options/statements for controlling paper size and styles

Other ad-hoc style setting within a SAS procedure

e.g. PROC REPORT

```
define text/display style(column)={just=left asis=on cellwidth=8.5 cm}  
                style(header)={just=left asis=on} flow id "Parameter";
```

Proc REPORT Tutorial. C. Zender. WUSS 2010

Beyond the Basic: Advanced REPORT Procedure Tips and Tricks Updated for SAS 9.2. A. McMahill Booth. SAS Global Forum 2011

Key points in ICH E3 referring to statistical outputs production

As per FDA Portable Document Format (PDF) Specifications – Style Requirements

- Black is the recommended font color. Any colors used should be tested prior to submission by printing sample pages from the document using a grayscale printer
- Additional rules as per eCTD guidance concerning
 - File size
 - File name (e.g. avoid punctuation, underscore, spaces, etc.)

Key points in ICH E3 referring to statistical outputs production

Structure / Titles / Numbering for section 14 and 16.x

- Standard sections contents/numbering is proposed
- A hierarchical structure
 - Output titles and sub-titles, and their associated bookmarks are limited to 4 levels as per eCTD guidance.

For example for section 14

14.1 DEMOGRAPHICS DATA

14.2 EFFICACY DATA

14.3 SAFETY DATA

14.3.1 Displays of Adverse Events

14.3.2 Listings o deaths, other SAE and Significant Aes

14.3.3 Narrative Deaths, Other serious.....

14.3.4 Abnormal Laboratory Value Listing (Each patient)

Agenda

- Introduction to ICH E3
- Key points in ICH E3 referring to statistical outputs production
- **ICH E3 Additional Considerations**
- Technical Solutions
 - Software requirements overview
 - In-house solutions
 - Facilitate the work of the medical writer
 - Other possible topics for discussion
- References

ICH E3 Additional Considerations



Still space for interpretation / individual preferences
e.g. medical writer

- Duplication of outputs in section 14 and in-text
- 16.4 for all trials, 16.4 and Subjects Profiles, 16.4 and SDTM
- Duplication of outputs (listings) in section 14 and 16.x, 16.2 and 16.4
- Exposure in section 14.3
- Concomitant Medications in section 14.1 or 14.3

ICH E3 Additional Considerations

Some recommendations – We must do it!

- Follow the eCTD and FDA PDF Specifications
 - Paper format including margins setting
 - Font style and size
 - Avoid use of colors
- Adhere to key items in E3 structure
 - 14.1 for all demographics / data generated prior to experimental drug expose
 - 14.2 for efficacy
 - 14.3 for safety including any 'interventions' (e.g. exposure)
 - 16.X at least listings explicitly mentioned in the ICH E3

Out of scope of the presentation «non clinical» domains e.g. PK

Agenda

- Introduction to ICH E3
- Key points in ICH E3 referring to statistical outputs production
- ICH E3 Additional Considerations
- Technical Solutions
 - **Software requirements overview**
 - In-house solutions
 - Facilitate the work of the medical writer
 - Other possible topics for discussion
- References

Technical Solutions

Software requirements overview

- Combine descriptive statistics including p-values for inferential tests
- Generates totals and subtotals within specified groups
- Full control of the denominator for percentage calculations
- Automatic rounding, formatting, and decimal point alignment of results
- Manages page changing based on user-defined groupings
- Headings span (multiple columns)
- Titles and footnote management
- Places information from a single record on multiple output lines
- Full control of titles and footnotes
- Allow creation of styled RTF tables for immediate use in Publishing software (e.g. WORD)
- Table of Contents Generation
- Management of template/standard libraries

Technical Solutions

Software requirements overview

■ SAS

- Procedures for output reporting e.g. TABULATE, REPORT, etc.
- Procedures for statistical techniques/methods e.g. LIFETEST, GLM, etc.
- ODS, Proc TEMPLATE, Proc DOCUMENT
- Macro
- No end-user application, No **proc CSR** or **proc TLF** yet

■ R

- Existing library for «R for Clinical Trial Reporting» FE Harrel (2007)

Technical Solutions

Software requirements overview

Others

- Pharmastat APT Analysis Library Tool for Clinical Trials Report Creation
- Dataceutics SAS/IntrNet based platform for Clinical Reporting
- ClinPlus
- SAS JMP Clinical

- SAS Drug and Device Development and other SAS tools for Life Science
- EntimICE
- Oracle Life Science

Still a bit away from the
push_the_bottom_away theory

Agenda

- Introduction to ICH E3
- Key points in ICH E3 referring to statistical outputs production
- ICH E3 Additional Considerations
- Technical Solutions
 - Software requirements overview
 - **In-house solutions**
 - Facilitate the work of the medical writer
 - Other possible topics for discussion
- References


Technical Solutions

In-house solutions (Sponsor)

Often each organization has **its own tools**/macro library/process

GBSOS - A Guidance for statistical outputs

5 GENERAL SPECIFICATIONS RELATED TO ALL OUTPUTS



□

Technical Solutions

In-house solutions (Sponsor)

Additional rules / **policy** for outputs numbering

14.1 Demographics

14.2 Efficacy

14.3 Safety

14.3.0 Extent of exposure*

14.3.1 Adverse events

14.3.2 Listing of deaths, SAEs, etc

14.3.3 Case narratives

14.3.4 Listing of abnormal lab values

14.3.5 Lab tables*

14.3.6 Other tables*

14.4 PK*

14.5 PD*

14.6 Other data*

* Sponsor addition

16.1.7 Randomization and Codes

16.1.9 Documentation of statistical methods

16.2.1 Discontinued subjects

16.2.2 Protocol deviations

16.2.3 Subj. excl. from efficacy analyses

16.2.4 Demographics

16.2.5 Compliance / drug conc. Data

16.2.6 Efficacy

16.2.7 Adverse events

16.2.8 Lab

16.1.6 Listings of patients receiving test drug(s)/investigational product from specific batches, where more than one batch was use

16.1.9 (out of scope) SAP or description of key stats items

FDA <http://www.fda.gov/ohrms/dockets/ac/09/briefing/2009-4430b1-56%20S01-01US%20Statistical%20Analysis%20Plan.pdf>

Technical Solutions

In-house solutions (Sponsor)

SDOT - A set of SAS macro to cover **standard** outputs

- TABS: Continuous / Categorical Standard Analysis Outputs
- AE: Adverse Events and Concomitant Medications
- PDF: Ad-hoc outputs
- LST2PS: PDF output production with hierarchical bookmarks

→ Started with excel outputs
→ Tried word outputs



.MHTM file

→ **PDF** preferable solution for section 14 and 16.x

→ Standard SAS .LST file read and transformed to PS rendered to PDF

- + More stable
- + Size of output file
- Less space available (monospace font)
- Less styling options


Agenda

- Introduction to ICH E3
- Key points in ICH E3 referring to statistical outputs production
- ICH E3 Additional Considerations
- Technical Solutions
 - Software requirements overview
 - In-house solutions
 - **Facilitate the work of the medical writer**
 - Other possible topics for discussion
- References

Technical Solutions

Facilitate the work of the medical writer

- Provide section 14 and 16.x in PDF format with **bookmarks** to facilitate the production of the final CSR



15.1 : DEMOGRAPHIC DATA
15.1.1 : Subject Disposition
Table 15.1.1.1 : ITT Population

Characteristic	Group A (N=36) N (%)	Group B (N=41) N (%)	Placebo (N=56) N (%)
<hr/>			
All Screened Subjects			
Safety Population	33 (91.7)	36 (87.8)	50 (89.3)
ITT Population	33 (91.7)	37 (90.2)	51 (91.1)
Per Protocol Population	23 (63.9)	24 (58.5)	38 (67.9)
Total number (%) of discontinued subjects	31 (86.1)	36 (87.8)	50 (89.3)
Reason For Discontinuation As Randomized	31 (100.0)	36 (100.0)	50 (100.0)
Adverse Event	5 (16.1)	5 (13.9)	11 (22.0)
Death	6 (19.4)	2 (5.6)	5 (10.0)
Inclusion And/Or Exclusion Criteria Not Fulfilled	0 (0.0)	0 (0.0)	1 (2.0)
Subject Withdrew Consent	3 (9.7)	0 (0.0)	5 (10.0)
Progressive Disease	14 (45.2)	21 (58.3)	19 (38.0)
Symptomatic Deterioration	0 (0.0)	0 (0.0)	3 (6.0)
Others	3 (9.7)	8 (22.2)	6 (12.0)

Technical Solutions

Facilitate the work of the medical writer
PDF Bookmark creation – In house solution (Sponsor)

Before

- Outputs where either generated in .XLS or RTF
- Rendered to PDF
- Bookmarks where created manually by the MW

Technical Solutions

Facilitate the work of the medical writer
PDF Bookmark creation – In house solution (Sponsor)

In-house solution (SAS macro)

- Standard SAS .LST output
- Rules for hierarchical titles
- .LST rendered to PDF and hierarchical titles captured from the .LST
- Postscript file with built-in bookmark from hierarchical titles automatically rendered to PDF

Technical Solutions

Facilitate the work of the medical writer

PDF Bookmark creation – In house solution (Sponsor)

In-house solution (SAS macro)

■ LST Rules for pagesize and linesize

Layout Number	Regulatory Approved	Number of lines	Number of characters per line
1	Yes	46	120
2	Yes	52	120
3	Yes ¹	46	128
4	Yes ¹	52	128
5	No	52	135
6	No	58	135
7	No	52	144
8	No	58	144

■ Example of **postscript** statements to control bookmarks

```

[/Count 3 /Title (Bookmarks root node) /Dest /First_Link /OUT pdfmark
[/Count 0 /Title (Link to page 1) /Dest /First_Link /OUT pdfmark
[/Count 1 /Title (Link to page 2) /Dest /Second_Link /OUT pdfmark
  [/Count 1 /Title (Link to page 3) /Dest /Third_Link /OUT pdfmark
    [/Count 0 /Title (Link to page 5) /Dest /Fifth_Link /OUT pdfmark
  [/Count 0 /Title (Link to page 4) /Dest /Fourth_Link /OUT pdfmark
  
```

Technical Solutions

Facilitate the work of the medical writer

PDF Bookmark creation – Possible solutions with SAS 9.x

- Default PDF bookmarked file
- ODS PROCLABEL to control standard SAS proc label (bookmark level 1)
- Proc options to control bookmark level 2 e.g. CONTENTS= in PROC REPORT
DESCRIPTION= in SAS/GRAPH procedures
 - Some procedures have more than 2 levels e.g. PROC GLM
- Control bookmarks through PROC TEMPLATE
- Full bookmarks control through PROC DOCUMENT

Technical Solutions

Facilitate the work of the medical writer

PDF Bookmark creation – Possible solutions with SAS 9.x - Example

Create a PDF file with 4 outputs with the following hierarchical bookmarks:

14.1 DEMOGRAPHICS DATA

14.1.2 Subject Accrual

Table 14.1.2.1 ITT Population

PROC FREQ

14.1.6 Demographics Characteristics

Table 14.1.6.1 ITT Population

PROC TABULATE

Listing 14.1.6.1 Detailed Listing

PROC REPORT

14.2 EFFICACY DATA

14.2.1 Primary Endpoint

Table 14.2.1.1 ITT Population


PROC LOGISTIC
with ODS SELECT

Technical Solutions

Facilitate the work of the medical writer

PDF Bookmark creation – Possible solutions with SAS 9.x - Example

The best result with ODS statements and PROC options



```
ods PDF file='MYFILE.pdf' style=MyStyle;
ods PROCLABEL='14.1 DEMOGRAPHICS DATA';
proc tabulate data=pts
CONTENTS="14.1.6 Demographics Characteristic";
```

...

```
run;
```

```
ods PDF close;
```

- Other possible statements controlling bookmarks generation:
 - PDFTOC=n
 - Control the nr. of level to be displayed (ODS option) NOPTITLE
 - Suppress standard proc title (ODS option) /CONTENTS='Label'
 - option of TABLES statement (proc FREQ)


Technical Solutions

Facilitate the work of the medical writer

PDF Bookmark creation – Possible solutions with SAS 9.x - Examples

The best result with ODS statements and PROC options

- Bookmarks not controlled through title statement
- Hierarchy within PROC
 - e.g. PROC LOGISTIC




- Not easy to control although further improvements are possible with template control (PROC TEMPLATE)

Technical Solutions

Facilitate the work of the medical writer

PDF Bookmark creation – Possible solutions with SAS 9.x – The new DOCUMENT concept

- SAS prior to v 8
 - PROC producing «DATA» and defining «STYLE» for only one type of output .LST
- SAS v 8
 - ODS introduced the concept of DATA and STYLE object as OUTPUT object
 - OUTPUT objects can be not stored



Technical Solutions

Facilitate the work of the medical writer

PDF Bookmark creation – Possible solutions with SAS 9.x – The new DOCUMENT concept

SAS 9 introduced the concept of **Document**

- ODS Output Objects in raw form stored in an **item store**
- Stored as **hierarchical** files
- Transform report **without rerunning** the analysis or repeating the database query by **modifying** and **replaying** an item store
- Control the report structure
- Absolute control over Table of Contents (e.g. PDF bookmarks)
- ODS DOCUMENT, PROC DOCUMENT, ODSDOCUMENT WINDOW

Technical Solutions

Facilitate the work of the medical writer

PDF Bookmark creation – Possible solutions with SAS 9.x – The new DOCUMENT concept

ODS DOCUMENT NAME=TLF(WRITE);

<SAS Proc Statement generating outputs>

ODS DOCUMENT CLOSE;

proc document name=TLF;

list / levels =all;

run;quit;


Listing of: \Work.Tlf\
Order by: Insertion
Number of levels: All

Obs	Path	Type	
1	\Freq#1	Dir	
2	\Freq#1\Table1#1	Dir	
3	\Freq#1\Table1#1\CrosstabFreqs#1	Crosstab	→ PROC FREQ Output
4	\Tabulate#1	Dir	
5	\Tabulate#1\Report#1	Dir	
6	\Tabulate#1\Report#1\Table#1	Table	→ PROC TABULATE Output
7	\Report#1	Dir	
8	\Report#1\Report#1	Dir	
9	\Report#1\Report#1\Report#1	Table	→ PROC REPORT Output
10	\Logistic#1	Dir	
11	\Logistic#1\ParameterEstimates#1	Table	→ PROC LOGISTIC Output

Technical Solutions

Facilitate the work of the medical writer

PDF Bookmark creation – Possible solutions with SAS 9.x – The new DOCUMENT concept




An interactive environment to modify the document

- Adding a node
- Modifying a node
- Rename a node
- Move a node
- Same actions for a table

Technical Solutions

Facilitate the work of the medical writer

PDF Bookmark creation – Possible solutions with SAS 9.x – The new DOCUMENT concept



Document modified with ODSDOCUMENT point and click tool

PDF recreated

```
ods pdf file="<my file>"
  style=MYSTYLE;
proc document name=TLF;
  replay ;
run;
ods pdf close;
```

		Arm	
		Arm A	Arm B
Sex			
Male	N	21	10
	%	52.50	47.50
Female	N	10	10
	%	52.63	47.37
Age (Yrs)			
	N	31	20
	Mean	50.94	53.00
	Min	19.0	20
	Max	85.0	87

Technical Solutions

Facilitate the work of the medical writer

PDF Bookmark creation – Possible solutions with SAS 9.x – The new DOCUMENT concept

The SAS code generated by the «Document Recorder» facility

```
proc document name=MyDoc.TLF(UPDATE);
```

```
/*Move outputs to correct section/level and change the title*/
```

```
SETLABEL Freq#1\Table1#1 '14.1.2 Subject Accrual';
```

```
DIR \Freq#1\Table1#1;
```

```
SETLABEL \CrossTabFreqs#1 'Table 14.1.2.1 Subject Accrual - ITT  
Population';
```

```
COPY \Tabulate#1\Report#1 TO \Freq#1\Report#1;
```

```
.....
```

```
<continue>
```

Technical Solutions

Facilitate the work of the medical writer

PDF Bookmark creation – Possible solutions with SAS 9.x – The new DOCUMENT concept

The SAS code generated by the «Document Recorder» facility

....

```
/* Create the missing level 2 for section 14.2 */
```

```
DIR \Logistic#1;
```

```
MAKE \Sub14_2_1;
```

```
SETLABEL \Sub14_2_1 '14.2.1 Primary Endpoint';
```

```
COPY \ParameterEstimates#1 TO Sub14_2_1#1\ParameterEstimates#1;
```

.....

```
quit;
```

Technical Solutions

Facilitate the work of the medical writer

PDF Bookmark creation – Possible solutions with SAS 9.x – The new DOCUMENT concept

Operation	PROC DOCUMENT	Windows	UNIX
Display the path of the current directory	<code>dir</code>	<code>chdir</code>	<code>pwd</code>
Change the current directory to <i>path</i>	<code>dir path</code>	<code>chdir path</code>	<code>cd path</code>
List the contents of the current directory or given path	<code>list <path></code>	<code>dir <path></code>	<code>ls <path></code>
Copy a path	<code>copy a to b</code>	<code>copy a b</code>	<code>cp a b</code>
Move a path	<code>move a to b</code>	<code>move a b</code>	<code>mv a b</code>
Create a new directory	<code>make path</code>	<code>mkdir path</code>	<code>mkdir path</code>
Create a symbolic link	<code>link a to b</code>	N/A	<code>ln -s a b</code>
Create a hard link	<code>link a to b / hard</code>	N/A	<code>ln a b</code>
Rename a path	<code>rename a to b</code>	<code>rename a b</code>	<code>mv a b</code>
Delete a path	<code>delete path</code>	<code>del path</code>	<code>rm path</code>
Current directory specifier	<code>^</code>	<code>.</code>	<code>.</code>
Parent directory specifier	<code>^^</code>	<code>..</code>	<code>..</code>

ODS DOCUMENT from scratch. KD Smith SAS Global Forum 2012

Technical Solutions

Facilitate the work of the medical writer

PDF Bookmark creation – Possible solutions with SAS 9.x – The new DOCUMENT concept

Operation	Command
List all documents in <i>library</i>	<code>doc library=<i>library</i></code>
Open <i>document</i> for update	<code>doc name=<i>document</i></code>
Close the current document	<code>doc close</code>
Delete <i>document</i>	<code>delete <i>document</i></code>
Import a data set, grseg, or text file to <i>path</i>	<code>import data grseg textfile=<i>name</i> to <i>path</i></code>
Create a new note at <i>path</i>	<code>note <i>path</i> "<i>text</i>"</code>
Set the label of <i>path</i>	<code>setlabel <i>path</i> "<i>text</i>"</code>
Set the <i>n</i> th line before the note of <i>path</i>	<code>obbnote<<i>n</i>> <i>path</i> "<i>text</i>"</code>
Set the <i>n</i> th line after the note of <i>path</i>	<code>obanote<<i>n</i>> <i>path</i> "<i>text</i>"</code>
Set the <i>n</i> th line of the title of <i>path</i>	<code>obtitle<<i>n</i>> <i>path</i> "<i>text</i>"</code>
Set the <i>n</i> th line of the subtitle of <i>path</i>	<code>obstitle<<i>n</i>> <i>path</i> "<i>text</i>"</code>
Set the <i>n</i> th line of the footnote of <i>path</i>	<code>obfootn<<i>n</i>> <i>path</i> "<i>text</i>"</code>
Control the page breaks of <i>path</i>	<code>obpage <i>path</i> / <after> <delete></code>
Display the template code for <i>path</i>	<code>obtempl <i>path</i></code>
Hide <i>path</i> from being replayed	<code>hide <i>path</i></code>
Unhide <i>path</i> from being replayed	<code>unhide <i>path</i></code>

ODS DOCUMENT from scratch. KD Smith SAS Global Forum 2012

Agenda

- Introduction to ICH E3
- Key points in ICH E3 referring to statistical outputs production
- ICH E3 Additional Considerations
- Technical Solutions
 - Software requirements overview
 - In-house solutions
 - Facilitate the work of the medical writer
 - **Other possible topics for discussion**
- References

Other possible topics for discussion related to statistical outputs production

- PhUSE/FDA Working Group (see Wiki Page for Development of Standard Scripts for Analysis and Programming)
- Layout examples in ADaM AE, TTE and ADaM examples in commonly used statistical analysis methods
- Analysis Results Metadata
- Traceability
- Validation / Quality Control
- Documentation / Procedures / Templates
- ADaM not covered but is should be considered as a statistical output

Agenda

- Introduction to ICH E3
- Key points in ICH E3 referring to statistical outputs production
- ICH E3 Additional Considerations
- Technical Solutions
 - Software requirements overview
 - In-house solutions
 - Facilitate the work of the medical writer
 - Other possible topics for discussion
- **References**

References

Regulatory

ICH E3. Structure and Content of Clinical Study Report

ICH E3. Questions and Answers. 7 June 2012

ICH E9. Statistical Principles for Clinical Trials

ICH M2 EWG. The Electronic Common Technical Document (eCTD)

FDA Portable Document (PDF) Specifications

Preparing Clinical Study Reports for eCTD. J Aitken. DIA 7th Annual Electronic Submission Conference 2008

SAS and ODS in General

The Greatest Hits: ODS Essentials Every User Should Know. C. Zender. NESUG 2011

A SAS Output Delivery System Menu for All Appetites and Applications. C. Parker. SAS Global Forum 2009

References

SAS and Other Useful Hints for Outputs Productions

Developing a Complete Picture of Patient Safety in Clinical Trials. RC Zink. RD Wolfinger. SESUG 2012

Supplementing Programmed Assisted Patient Narrative (PANs) with Graphs Using SAS. F. Yeh M. Munsaka. PharmaSUG 2012

Advanced RTF Layout with SAS. K. Glab. PhUSE 2007

Proc REPORT Tutorial. C. Zender. WUSS 2010

Beyond the Basic: Advanced REPORT Procedure Tips and Tricks Updated for SAS 9.2. A. McMahon Booth. SAS Global Forum 2011

RTF Tagset for Use in Clinical Reporting. M. Andersen. PhUSE SDE 2012

Zoom, Zoom: Get your document to scale on all paper size. D. O'Connor. SAS Global Forum 2010

References

Generating figures

Superior gRaphics in Statistical Reports. S. Bamnote. PhUSE 2012

Using SAS GTL to visualize your data when there is too much of it to visualize. P. Watts N. Derby. SAS Global Forum 2012

Incorporating graphics into Summary Report Tables using ODS and GTL. Q. Chen. PharmaSUG 2011

Tips and tricks for clinical graphics using ODS Graphics. S. Matange. SAS Global Forum 2011

Clinical Trial Reporting with SAS ODS Graphics. HR. Pauli DJ. Garbutt. PhUSE 2009

References

SAS and Bookmakrs / Table of Contents Generation

Creating a Customized Table of Contents in ODS RTF Documents. E. Small. NESUG 2006

Let's Give'Em Something to TOC about: Transforming the Table of Contents of your PDF file. B. Lawhorn. SAS Global Forum 2011

Using Proc DOCUMENT to Modify PDF Bookmakrs Generated by Proc FREQ. SM. Dorinski. NESUG 2008

ODS DOCUMENT from scratch. KD Smith SAS Global Forum 2012

Creating Define.PDF with SAS Version 9.3 ODS RTF. E. Li C. Chesbrough. PharmaSUG 2012


Questions

Headquarters:
Cambridge, MA
+1.617.661.2011

Offices:
Philadelphia, PA
+1.610.994.9830
San Jose, CA
+1.857.928.6230
Paris, FRANCE
+33.1.40.331.776
Pune, INDIA
+91.98509.70522

Cytel Clinical Research Services is trusted by drug, biologic and medical device developers worldwide. In fact, all 25 of the leading global biopharmaceutical companies use Cytel technology.

Cytel 675 Massachusetts Ave
Cambridge MA 02139
info@cytel.com angelo.tinazzi@cytel.com



Cytel Inc. Geneva Branch
ICC Building C, 2nd Floor
Route de Pré-Bois 20
CH 1215 Geneva

